Our sales team is thrilled to announce that we will be attending this year’s American Society of Hematology's (ASH) 65th Annual Meeting in San Diego, CA! We are looking forward to engaging with fellow professionals, sharing our latest research, and exploring the newest advancements in hematology. It’s a fantastic opportunity to connect, learn, and contribute to the future of hematology. If you’re attending, we’d love to meet up and discuss how we can collaborate with you on your clinical trials. Schedule a meeting and meet us https://lnkd.in/gQmY2tFt #ASH2024 #Hematology #InnovationInMedicine #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics?#immunoonocology ?#research #clinicaltrials #Pharmaceuticals #NuclearMedicine #Innovation
ImaginAb
生物技术研究
Inglewood,CA 5,923 位关注者
Be the lead diagnostic and treatment choice...helping patients live better and healthier lives.
关于我们
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET?) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
- 网站
-
https://www.imaginab.com
ImaginAb的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Inglewood,CA
- 类型
- 私人持股
- 创立
- 2007
- 领域
- Antibody engineering and imaging、Personalized medicine、Therapeutic management、Clinical development、PET radiopharmaceuticals、89Zr-、PET Imaging、Minibody、Biomarker、Immunocology、CD8、T cells、Immunology、Oncology、cancer和CD8 Tracer
地点
ImaginAb员工
动态
-
Read our latest article: https://lnkd.in/gKgvJdvc Accurately assessing immune response in cancer patients undergoing immunotherapy is crucial for evaluating treatment efficacy and predicting outcomes. See how CD8+ T cells and the Immunoscore are two key biomarkers that are gaining attention in immunooncology. #ImmunoOncology #CancerTreatment #InnovationInHealthcare #CD8ImmunoPET #immunooncology #immunotherapy #oncology #medicalresearch
-
Our team enjoyed the Society for Immunotherapy of Cancer (SITC)'s Annual Meeting this year, and it was an unforgettable experience! From groundbreaking research presentations to inspiring keynote speeches, the event was a hub of innovation and collaboration in the field of cancer immunotherapy. Networking with fellow professionals and exchanging ideas with pioneers in the field was truly enriching. The discussions and insights gained will undoubtedly shape the future of our work and drive us closer to new breakthroughs in cancer treatment. A huge thank you to the organizers, speakers, and all the attendees who made this event so impactful. #SITC2024 #CancerImmunotherapy #MedicalInnovation #Networking #FutureOfMedicine #ImaginAb #CD8 #CD8ImmunoPET #RPT
-
+5
-
Schedule a meeting by visiting: https://lnkd.in/gbqx5v9k Meet our Sales team at the Society for Immunotherapy of Cancer (SITC) Annual Meeting at booth #630 on November 8th & 9th. Learn how you can use CD8 Imaging in your clinical trials. Schedule a meeting today! #CD8ImmunoPET #immunooncology #pharma #biotech #SITC24?#radiopharmaceutical #PETCT #nuclearmedicine #theranostics #RPT
-
ImaginAb is proud to support Breast Cancer Awareness Month. We are committed to advancing the fight against breast cancer through our research and partnerships. Here is a look at two collaborative research studies that focus on metastatic breast cancer research: Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4+ and CD8+ T cells - https://lnkd.in/ghaiBSc9 Abstract PO1-20-12: CD8+ Tumor Infiltrating Lymphocytes Turn a Cold Tumor Hot in Metastatic Breast Cancer -https://lnkd.in/gEBVWMU8 Join us in raising awareness and supporting those affected by breast cancer. #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics?#immunoonocology ?#research #clinicaltrials #BreastCancerResearch #Pharmaceuticals #BreastCancerAwarenessDay
-
Read here: https://lnkd.in/g5gFrxJQ Dive into our latest article, "Pseudoprogression vs. True Progression in Immunotherapy: Challenges and Evaluation." Discover the complexities of distinguishing between pseudoprogression and true disease progression in the realm of immuno-oncology. Learn about the critical role of imaging techniques and the phenomenon of tumor flare. Don't miss out on this insightful read! Read here: https://lnkd.in/g5gFrxJQ #ImmunoOncology #CancerTreatment #Pseudoprogression #InnovationInHealthcare #CD8ImmunoPET #immunooncology #immunotherapy #oncology #medicalresearch
-
A huge thank you to the European Association of Nuclear Medicine (EANM) for organizing an incredible conference! The sessions were insightful, the networking opportunities were invaluable, and the overall experience was truly inspiring. We’re looking forward to next year’s meeting! #ImaginAb #CD8ImmunoPET #RPT #biotech #theranostics?#immunoonocology ?#research #clinicaltrials #Pharmaceuticals #EANM24 #EANM #EANM2024 #NuclearMedicine #Innovation
-
+1
-
Schedule a meeting by visiting: https://lnkd.in/gbqx5v9k We are thrilled to announce that we will exhibit at this year’s Society for Immunotherapy of Cancer (SITC)’s 39th Annual Meeting! Our team is excited to connect with industry professionals and learn about the latest advancements in cancer research. Meet with Kristin Schmiedehausen, MD, Calmen Tihansky, Suzanne Bissonnette, Elizabeth Thomas and Clinique Burrell, MPA to get the latest updates on ImaginAb and CD8 ImmunoPET?. Visit us at booth #630 #CD8ImmunoPET #immunooncology #pharma #biotech #SITC24 ?#radiopharmaceutical #PETCT #nuclearmedicine #theranostics #RPT #ImaginAb
-
Check our latest Perspective’s blog by Matthew Hoover. Explore the transformative power of immuno-oncology therapies targeting CTLA-4, PD-1, and PD-L1, enhancing the immune system’s ability to fight tumors. While offering new hope, these treatments also present unique challenges, including immune-related adverse events (irAEs) that mirror autoimmune disorders and can impact any organ system. Early detection and management of irAEs are vital for patient outcomes. This blog delves into traditional and innovative methods for identifying irAEs, from clinical observation to advanced molecular imaging, ensuring optimized treatment and patient care. Read here: https://lnkd.in/gQgP4X99 #ImmunoOncology #CancerTreatment #irAEs #InnovationInHealthcare #CD8ImmunoPET #immunooncology #immunotherapy
-
Calmen Tihansky is attending Arena International Events Group's 16th Annual Outsourcing in Clinical Trials New England 2024 event on October 23 & 24th. Explore the potential of CD8 ImmunoPET? in your clinical trials, by scheduling a meeting?with Calmen by reaching out to him directly or email him at [email protected] Industry experts will share their knowledge on various topics related to clinical trials, including clinical operations, outsourcing, technology, patient recruitment, and more. #CD8ImmunoPET #immunooncology #pharma #biotech #theranostics??#immunooncology #PETCT #nuclearmedicine #clinicaltrials #RareDiseases #Biopharma #ClinicalOperations #Innovation